These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 27033559

  • 1. Successful transfer to sulfonylureas in KCNJ11 neonatal diabetes is determined by the mutation and duration of diabetes.
    Babiker T, Vedovato N, Patel K, Thomas N, Finn R, Männikkö R, Chakera AJ, Flanagan SE, Shepherd MH, Ellard S, Ashcroft FM, Hattersley AT.
    Diabetologia; 2016 Jun; 59(6):1162-6. PubMed ID: 27033559
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study.
    Bowman P, Sulen Å, Barbetti F, Beltrand J, Svalastoga P, Codner E, Tessmann EH, Juliusson PB, Skrivarhaug T, Pearson ER, Flanagan SE, Babiker T, Thomas NJ, Shepherd MH, Ellard S, Klimes I, Szopa M, Polak M, Iafusco D, Hattersley AT, Njølstad PR, Neonatal Diabetes International Collaborative Group.
    Lancet Diabetes Endocrinol; 2018 Aug; 6(8):637-646. PubMed ID: 29880308
    [Abstract] [Full Text] [Related]

  • 3. Molecular Genetics, Clinical Characteristics, and Treatment Outcomes of KATP-Channel Neonatal Diabetes Mellitus in Vietnam National Children's Hospital.
    Ngoc CTB, Dien TM, De Franco E, Ellard S, Houghton JAL, Lan NN, Thao BP, Khanh NN, Flanagan SE, Craig ME, Dung VC.
    Front Endocrinol (Lausanne); 2021 Aug; 12():727083. PubMed ID: 34566892
    [Abstract] [Full Text] [Related]

  • 4. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
    Pearson ER, Flechtner I, Njølstad PR, Malecki MT, Flanagan SE, Larkin B, Ashcroft FM, Klimes I, Codner E, Iotova V, Slingerland AS, Shield J, Robert JJ, Holst JJ, Clark PM, Ellard S, Søvik O, Polak M, Hattersley AT, Neonatal Diabetes International Collaborative Group.
    N Engl J Med; 2006 Aug 03; 355(5):467-77. PubMed ID: 16885550
    [Abstract] [Full Text] [Related]

  • 5. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations.
    Rafiq M, Flanagan SE, Patch AM, Shields BM, Ellard S, Hattersley AT, Neonatal Diabetes International Collaborative Group.
    Diabetes Care; 2008 Feb 03; 31(2):204-9. PubMed ID: 18025408
    [Abstract] [Full Text] [Related]

  • 6. Successful transfer from insulin to oral sulfonylurea in a 3-year-old girl with a mutation in the KCNJ11 gene.
    Al-Mahdi M, Al Mutair A, Al Balwi M, Hussain K.
    Ann Saudi Med; 2010 Feb 03; 30(2):162-4. PubMed ID: 20220270
    [Abstract] [Full Text] [Related]

  • 7. A Kir6.2 mutation causing severe functional effects in vitro produces neonatal diabetes without the expected neurological complications.
    Tammaro P, Flanagan SE, Zadek B, Srinivasan S, Woodhead H, Hameed S, Klimes I, Hattersley AT, Ellard S, Ashcroft FM.
    Diabetologia; 2008 May 03; 51(5):802-10. PubMed ID: 18335204
    [Abstract] [Full Text] [Related]

  • 8. Case report: Better late than never, but sooner is better: switch from CSII to sulfonylureas in two patients with neonatal diabetes due to KCNJ11 variants.
    Mancioppi V, Pozzi E, Zanetta S, Missineo A, Savastio S, Barbetti F, Mellone S, Giordano M, Rabbone I.
    Front Endocrinol (Lausanne); 2023 May 03; 14():1143736. PubMed ID: 37251668
    [Abstract] [Full Text] [Related]

  • 9. Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene.
    Tonini G, Bizzarri C, Bonfanti R, Vanelli M, Cerutti F, Faleschini E, Meschi F, Prisco F, Ciacco E, Cappa M, Torelli C, Cauvin V, Tumini S, Iafusco D, Barbetti F, Early-Onset Diabetes Study Group of the Italian Society of Paediatric Endocrinology and Diabetology.
    Diabetologia; 2006 Sep 03; 49(9):2210-3. PubMed ID: 16816952
    [No Abstract] [Full Text] [Related]

  • 10. Functional effects of mutations at F35 in the NH2-terminus of Kir6.2 (KCNJ11), causing neonatal diabetes, and response to sulfonylurea therapy.
    Proks P, Girard C, Baevre H, Njølstad PR, Ashcroft FM.
    Diabetes; 2006 Jun 03; 55(6):1731-7. PubMed ID: 16731836
    [Abstract] [Full Text] [Related]

  • 11. Permanent neonatal diabetes by a new mutation in KCNJ11: unsuccessful switch to sulfonylurea.
    Lau E, Correia C, Freitas P, Nogueira C, Costa M, Saavedra A, Costa C, Carvalho D, Fontoura M.
    Arch Endocrinol Metab; 2015 Dec 03; 59(6):559-61. PubMed ID: 26331221
    [Abstract] [Full Text] [Related]

  • 12. Successful sulfonylurea treatment of a neonate with neonatal diabetes mellitus due to a new KCNJ11 mutation.
    Ješić MM, Ješić MD, Maglajlić S, Sajić S, Necić S.
    Diabetes Res Clin Pract; 2011 Jan 03; 91(1):e1-3. PubMed ID: 21056492
    [Abstract] [Full Text] [Related]

  • 13. Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers.
    Stanik J, Gasperikova D, Paskova M, Barak L, Javorkova J, Jancova E, Ciljakova M, Hlava P, Michalek J, Flanagan SE, Pearson E, Hattersley AT, Ellard S, Klimes I.
    J Clin Endocrinol Metab; 2007 Apr 03; 92(4):1276-82. PubMed ID: 17213273
    [Abstract] [Full Text] [Related]

  • 14. Diabetes and hypoglycaemia in young children and mutations in the Kir6.2 subunit of the potassium channel: therapeutic consequences.
    Flechtner I, de Lonlay P, Polak M.
    Diabetes Metab; 2006 Dec 03; 32(6):569-80. PubMed ID: 17296510
    [Abstract] [Full Text] [Related]

  • 15. Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene.
    Slingerland AS, Nuboer R, Hadders-Algra M, Hattersley AT, Bruining GJ.
    Diabetologia; 2006 Nov 03; 49(11):2559-63. PubMed ID: 17047922
    [Abstract] [Full Text] [Related]

  • 16. Neonatal diabetes caused by a homozygous KCNJ11 mutation demonstrates that tiny changes in ATP sensitivity markedly affect diabetes risk.
    Vedovato N, Cliff E, Proks P, Poovazhagi V, Flanagan SE, Ellard S, Hattersley AT, Ashcroft FM.
    Diabetologia; 2016 Jul 03; 59(7):1430-1436. PubMed ID: 27118464
    [Abstract] [Full Text] [Related]

  • 17. Detection of KCNJ11 gene mutations in a family with neonatal diabetes mellitus: implications for therapeutic management of family members with long-standing disease.
    Abbasi F, Saba S, Ebrahim-Habibi A, Sayahpour FA, Amiri P, Larijani B, Amoli MM.
    Mol Diagn Ther; 2012 Apr 01; 16(2):109-14. PubMed ID: 22471336
    [Abstract] [Full Text] [Related]

  • 18. Transient neonatal diabetes with two novel mutations in the KCNJ11 gene and response to sulfonylurea treatment in a preterm infant.
    Siklar Z, Ellard S, Okulu E, Berberoğlu M, Young E, Savaş Erdeve S, Mungan IA, Hacihamdioğlu B, Erdeve O, Arsan S, Oçal G.
    J Pediatr Endocrinol Metab; 2011 Apr 01; 24(11-12):1077-80. PubMed ID: 22308870
    [Abstract] [Full Text] [Related]

  • 19. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes.
    Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS, Howard N, Srinivasan S, Silva JM, Molnes J, Edghill EL, Frayling TM, Temple IK, Mackay D, Shield JP, Sumnik Z, van Rhijn A, Wales JK, Clark P, Gorman S, Aisenberg J, Ellard S, Njølstad PR, Ashcroft FM, Hattersley AT.
    N Engl J Med; 2004 Apr 29; 350(18):1838-49. PubMed ID: 15115830
    [Abstract] [Full Text] [Related]

  • 20. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus.
    Babenko AP, Polak M, Cavé H, Busiah K, Czernichow P, Scharfmann R, Bryan J, Aguilar-Bryan L, Vaxillaire M, Froguel P.
    N Engl J Med; 2006 Aug 03; 355(5):456-66. PubMed ID: 16885549
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.